Surreal illustration representing the interconnectedness of memory loss, aging, and behavioral changes in Alzheimer's disease.

Beyond Memory Loss: Understanding and Managing Behavioral Changes in Alzheimer's

Jordan Keane monogram
Jordan Keane in Health & Wellness November 2026 • 3 min read.

"A practical guide to recognizing, addressing, and improving the quality of life for individuals experiencing behavioral and psychological symptoms of Alzheimer's disease."


Alzheimer's disease (AD) is often primarily associated with memory loss, but the condition also brings a range of behavioral and psychological symptoms (BPSD) that can significantly impact patients and caregivers. These symptoms, which include agitation, depression, delusions, and aggression, present complex challenges in care and management.

In Japan, there are restrictions on medicines specifically approved for treating BPSD in AD, and atypical antipsychotics are used cautiously due to concerns about increased mortality in elderly patients. Despite these limitations, managing BPSD is crucial for improving the quality of life for those living with AD.

This article explores the intricate relationship between aging, disease progression, and BPSD in Alzheimer's disease. We aim to provide practical insights into understanding and managing these challenging symptoms, drawing from research and clinical implications to inform effective care strategies.

AI Search Multiple angles on this topic

Neck Exercise Guidance

The NHS inform guidance addresses exercises for new neck muscle or joint problems and emphasizes restoring movement and strength after a neck problem. NHS Ayrshire & Arran reports that exercise can improve symptoms associated with spinal pain, while noting that there is no single exercise prescription because pain is complex. A WWL leaflet recommends exercising three to four times per week with at least one recovery day, adjusting activity according to pain levels. These sources concern neck pain rather than Alzheimer's disease or behavioral change.

Evidence Limitations

No subsection-specific sources were provided for standard approaches to behavioral changes in Alzheimer's disease. In general, management decisions should be individualized and reviewed with qualified healthcare professionals. The available material does not support specific claims about accepted methods, their effectiveness, or their limitations.

Historical Context

No subsection-specific sources were provided for the historical development of Alzheimer's behavioral-care practices. A reliable historical account would require sources addressing milestones in dementia research, diagnosis, caregiving, or treatment. Those details cannot be established from the supplied material.

Unraveling the Link: How Aging and Alzheimer's Shape Behavior

Surreal illustration representing the interconnectedness of memory loss, aging, and behavioral changes in Alzheimer's disease.

To better understand how aging and disease progression affect BPSD in AD, a study evaluated patients referred for AD treatment due to their BPSD. Researchers collected demographic data, assessed cognitive function using the Mini-Mental State Examination (MMSE), and evaluated BPSD using the Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD).

The study divided Alzheimer's patients into groups based on age and cognitive performance to analyze how these factors influence the manifestation of BPSD. This approach revealed key insights into how these symptoms evolve as the disease progresses.

  • Age-Related Differences: Older patients exhibited a connection between psychotic symptoms (delusions, hallucinations) and mood disturbances (anxiety, phobia), suggesting that these symptoms can merge as individuals age.
  • Cognitive Performance: Patients with lower MMSE scores showed a merging of psychotic symptoms, mood disturbances, and aggressiveness, indicating that cognitive decline can lead to a convergence of behavioral issues.
AI Search Multiple angles on this topic

Unrelated Technology Updates

The supplied sources do not present research or reviews concerning Alzheimer's disease or behavioral changes. One Microsoft article assumes that readers already have an Azure Foundry project and resource deployed in Microsoft Foundry. Another source introduces Microsoft Ink Canvas as an AI-powered, pen-first experience, while the remaining sources discuss SQL Server migration and updating Windows drivers. None of these snippets supports conclusions about current Alzheimer's research.

Insufficient Evidence

No subsection-specific sources were provided for counterarguments, failed interventions, or limitations in managing Alzheimer's behavioral changes. Such claims should not be inferred from unrelated material. The available evidence is therefore insufficient to identify disputed findings or documented failures.

No Supported Comparison

No subsection-specific sources were provided for comparing approaches to Alzheimer's behavioral changes. Comparisons between interventions, care settings, or outcomes would require sources that directly evaluate those alternatives. The supplied material does not support a factual comparative analysis.

These findings suggest that as Alzheimer’s disease advances, the distinct categories of BPSD may become less defined, requiring a more integrated approach to treatment and care.

Optimizing Treatment Strategies: A Path Forward

Considering the complex interplay between aging, cognitive decline, and BPSD, treatment strategies should be carefully tailored to each patient's unique presentation. A key consideration is whether to treat the underlying depression or target the psychotic symptoms directly. The research suggests that in later stages of AD, it may be more effective to address the mood and behavioral symptoms together, given their interconnectedness.

AI Search Multiple angles on this topic

Evidence-Based Synthesis

No subsection-specific sources were provided for a synthesis of evidence or expert commentary on Alzheimer's behavioral changes. A responsible synthesis would need direct clinical, research, or professional sources. The supplied material does not justify conclusions about causes, management, or outcomes.

No Relevant Outlook Evidence

The supplied sources do not provide evidence about future directions in Alzheimer's research or behavioral care. They consist of unrelated Data Lounge discussion pages, including one snippet that criticizes an interviewer's research and another that provides no description. These materials cannot support projections about emerging treatments, technologies, or care models.

Support Access

The only supplied source for this subsection is Microsoft's contact page, which directs users to solutions for common problems or to a support agent. It does not address Alzheimer's disease, dementia care, healthcare systems, caregiving, inequality, or other systemic challenges. No broader context can be responsibly drawn from this source.

Unrelated Event Listings

The supplied sources are event listings for Bill Bailey at First Direct Arena in Leeds on 28 November 2026. The listings give differing start times, including 6:00 PM and 8:00 PM, and report ticket information such as prices starting at £46 plus fees and StubHub's FanProtect Guarantee. They do not address Alzheimer's disease, behavioral change, caregiving, or real-world health impacts.

BPSD prevalence across dementia types

  • 32% of patientsIn pooled estimates across dementia types, apathy was most prevalent at 32%; depression and anxiety were each 29%, while irritability and agitation or aggression were each 27%. These estimates describe symptom prevalence, not treatment effects.[1]

How assessment and intervention findings differ

In a comparison with controls, TAP did not improve agitation or aggression at three months, while caregiver wellbeing and confidence using activities improved; assistance needs for daily activities also differed. These outcomes show that symptom change and caregiver or functional outcomes need not move together.[2]

A citalopram comparison reported a greater QTc interval increase than placebo, while a review of FDA trial data reported elevated mortality with atypical antipsychotics relative to placebo. These are distinct safety findings for different treatments and should not be treated as a direct comparison between the treatments.[3] [4]

The brexpiprazole report identifies limited treatment duration and calls for longer-term efficacy and safety information, particularly for cognition and mortality. That leaves its cited treatment findings bounded by the follow-up described there.[5]

What remains unresolved about symptoms and care

  • How do abnormalities in the prefrontal and subcortical limbic regions relate to particular neuropsychiatric symptoms, given that the precise contribution of these changes to Alzheimer's progression and symptoms remains unresolved?[6] [7]
  • How do medical, environmental, and caregiver circumstances shape symptom expression, and how much do they complicate symptom categorization?[8]

Sources

  1. Prevalence of Behavioral and Psychological Symptoms of Dementia in Community-Dwelling Dementia Patients: A Systematic Review (pmc.ncbi.nlm.nih.gov)
  2. Effects of the tailored activity program (TAP) on dementia-related symptoms, health events and caregiver wellbeing: a randomized controlled trial (pmc.ncbi.nlm.nih.gov)
  3. Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial (pmc.ncbi.nlm.nih.gov)
  4. A review on mortality risks associated with antipsychotic use in behavioral and psychologic symptoms of dementia (BPSD) (pmc.ncbi.nlm.nih.gov)
  5. Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia (pmc.ncbi.nlm.nih.gov)
  6. The neural basis of neuropsychiatric symptoms in Alzheimer’s disease (pmc.ncbi.nlm.nih.gov)
  7. Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns (link.springer.com)
  8. Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What are the common behavioral and psychological symptoms (BPSD) associated with Alzheimer's disease?

The behavioral and psychological symptoms (BPSD) of Alzheimer's disease (AD) encompass a range of challenges. These include agitation, depression, delusions, and aggression. These symptoms can significantly impact both the individuals diagnosed with AD and their caregivers, making management crucial for improving the quality of life for those living with AD.

2

How does aging influence the manifestation of behavioral and psychological symptoms (BPSD) in Alzheimer's disease?

A study evaluated patients referred for AD treatment. The results suggested that older patients exhibited a connection between psychotic symptoms (delusions, hallucinations) and mood disturbances (anxiety, phobia). This indicates that as individuals age, these distinct categories of BPSD can merge. The interconnectedness necessitates an integrated approach to treatment, addressing both mood and psychotic symptoms concurrently.

3

What role does cognitive decline play in the convergence of behavioral and psychological symptoms (BPSD) in Alzheimer's disease?

Cognitive decline, as assessed by the Mini-Mental State Examination (MMSE), is a significant factor in the manifestation of BPSD. Patients with lower MMSE scores showed a merging of psychotic symptoms, mood disturbances, and aggressiveness. This convergence highlights that as Alzheimer’s disease progresses and cognitive abilities diminish, the distinct categories of BPSD become less defined, demanding a more holistic and integrated care strategy.

4

Are there any limitations in the treatment of behavioral and psychological symptoms (BPSD) in Alzheimer's disease?

Yes, there are limitations, particularly regarding pharmacotherapy. In Japan, there are restrictions on medicines specifically approved for treating BPSD in AD. Moreover, atypical antipsychotics are used cautiously due to concerns about increased mortality in elderly patients. Despite these challenges, managing BPSD is paramount for improving the quality of life for those living with AD, and the implications underscore the need for alternative or complementary therapeutic approaches.

5

How should treatment strategies for behavioral and psychological symptoms (BPSD) be optimized in Alzheimer's disease?

Treatment strategies should be carefully tailored to each patient's unique presentation, considering the complex interplay between aging, cognitive decline, and BPSD. A critical consideration is whether to treat the underlying depression or target the psychotic symptoms directly. The research suggests that in later stages of AD, it may be more effective to address the mood and behavioral symptoms together, given their interconnectedness. This integrated approach can lead to better outcomes and improved quality of life for patients.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.